ClinicalTrials.gg
CompletedNCT03684265Updated Nov 22, 2019Results posted

A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets

A Phase 1 interventional study of Meloxicam Capsule (Test) and Meloxicam Tablet (Reference) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of the study is to investigate the relative bioavailability of Movalis capsules 15 mg (Test, T) versus Movalis tablets 15 mg (Reference, R).

The secondary objective of the study is to establish bioequivalence of Movalis capsules 15 mg (Test, T) versus Movalis tablets 15 mg (Reference, R).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18-45, inclusive.
  • by Quetelet between 18.50 -29.99 kg/m2, inclusive.
  • The verified diagnosis is "healthy" according to the conclusion investigator according to the information in the anamnesis, the results of the physical examination, the (ECG), the results of measurement of vital signs of the body (blood pressure, heart rate, breathing rate and body temperature), and laboratory indicators.
  • Pre-conducting standard clinical and laboratory and instrumental studies did not reveal the presence of any diseases and abnormalities.
  • Systolic blood pressure not less than 100 mm Hg. and not higher than 139 mm Hg. diastolic blood pressure not less than 70 mm Hg. and not more than 90 mm Hg. the heart rate is not less than 60 beats per minute and not more than 90 beats per minute, the frequency of respiratory movements is within the range of 12-20 per minute.
  • Ability to understand and accept the explanation of the study; the written of the volunteer to participate in the study in accordance with applicable law.
  • Female subjects of who agree on using double-barrier from a screening visit to 30 days after the last administration of the study drug, inclusive. If a female is (no menses for at least 1 year) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) she will be exempt from the requirement. In case of using oral contraceptives, these should be withdrawn at least 2 months before the study.
  • Male subjects who agree on using effective contraception (barrier contraceptive methods) from a screening visit to 30 days after the last administration of the study drug, inclusive.

Exclusion criteria

Exclusion criteria:

  • Drug intolerance of any drug.
  • Allergic history.
  • Acute infectious diseases or allergic reactions requiring treatment (including drug allergy), less than 4 weeks before the screening.
  • Surgical interventions on the gastrointestinal tract (with the exception of appendectomy), which can have a significant effect on the absorption or metabolism of study drugs.
  • Known to meloxicam or any of the test and reference products.
  • Known hypersensitivity to other Non- anti-inflammatory drug (NSAIDs): subjects who have developed signs of asthma, nasal polyps, angio-oedema or urticarial following the administration of acetylsalicylic acid or other NSAIDs.
  • Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine system, as well as diseases of the gastrointestinal tract, liver, kidneys, blood, or other conditions that make it impossible for the volunteer to participate in the study according to the investigator opinion.
  • The results of standard laboratory and instrumental methods of examination, obtained during the screening, go beyond normal values.
  • History of gastro-intestinal ulceration/ perforation or bleeding; history of within 5 years before the screening.
  • Positive results of blood tests for infections (, syphilis, or C) at screening.
  • A positive alcohol test at screening.
  • A positive urine drug test (cannabis, benzodiazepines, barbiturates, opiates, cocaine, and amphetamines) at screening.
  • Pregnancy or breastfeeding.
  • Any diet, for example, vegetarian, for 2 weeks before the first day of screening.
  • Alcohol intake more than 10 units. alcohol per week (1 unit of alcohol is equivalent to ½ liter of beer, 200 ml of wine or 50 ml of alcohol) or anamnestic information about alcoholism, drug addiction, abuse of medicines.
  • The inability to be without food for at least 12 hours and the inability to take the drug on an empty stomach.
  • Blood donation (≥ 450 ml) within 3 months before screening.
  • Depot injections, the installation of intrauterine hormonal therapy systems or implants of any drugs for 6 months before the screening;
  • For women: use of hormonal less than 2 months before the screening.
  • Regular drug intake within 2 weeks before the screening.
  • Intake of systemic drugs known to alter liver function (barbiturates, omeprazole, cimetidine) within 4 weeks before the screening.
  • For women: volunteers with preserved who had unprotected intercourse with an unsterilized male partner for 30 days before the screening
  • Participation in another clinical trial within 3 months before the screening.
  • Difficult access to the vein, complicating or making it impossible to install a catheter and frequent blood sampling.
  • Smoker (≥10 cigarettes or ≥ 3 pipes per day).
  • Inability to refrain from smoking on study days.
  • Volunteers who do not want or are unable to give up alcohol and excessive physical exertion from the first day of screening and before the visit of follow-up.
  • Volunteers who are unwilling or unable to refuse drinks and food containing methylxanthines (coffee, tea, cola, energy drinks, chocolate, etc.) and grapefruit / grapefruit juice, Seville oranges (sour or bitter oranges) and their juices, and dietary supplements and products including St. John's wort (Hypericum perforatum) from the first day of screening and until a follow-up visit.
  • Volunteers who lead a lifestyle (including night work and extreme physical activities such as sports or weight lifting), which can make it difficult to interpret the laboratory data obtained during the study.
  • Volunteers who do not intend to comply with the study regime.
  • Volunteers who are obviously or probably, in the opinion of the investigator, are not able to understand and evaluate the information on this study in the process of signing the ICF, in particular regarding the expected risks and possible discomfort.
  • The presence of volunteers dehydration due to diarrhea, vomiting or other cause within the last 24 hours before the first day of screening.
  • The presence of volunteers attacks of seizures, epilepsy and any other neurological disorders in the anamnesis
  • Recent cerebrovascular bleeding or established systemic bleeding disorders.
  • Known lactose intolerance.
  • Reports difficulty for swallowing tablets or capsules.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Test to Reference

    Drug: Meloxicam Capsule (Test) · Drug: Meloxicam Tablet (Reference)

  • Experimental
    Reference to Test

    Drug: Meloxicam Capsule (Test) · Drug: Meloxicam Tablet (Reference)

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t)

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-t). Standard error is actually Geometric standard error.

    Time frame: Baseline (pre-dose), 0.5 hours (h), 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 10.0h, 12.0h, 24.0h, 32.0h, 48.0h and 72.0h post-dose

  2. Maximum Measured Concentration of the Analyte in Plasma (Cmax)

    Maximum measured concentration of the analyte in plasma (Cmax). Standard error is actually Geometric standard error.

    Time frame: Baseline (pre-dose), 0.5 hours(h), 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 10.0h, 12.0h, 24.0h, 32.0h, 48.0h and 72.0h post-dose

Secondary outcomes

  1. Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Standard error is actually Geometric standard error.

    Time frame: Baseline (pre-dose), 0.5 hours(h), 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 10.0h, 12.0h, 24.0h, 32.0h, 48.0h and 72.0h post-dose

07

Results

Posted Nov 22, 2019

Participant flow

The trial was a randomised, two-period, two sequences, single-dose, open-label, and crossover trial in healthy male and female subjects in fasting conditions.

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneMovalis® Capsules (T), Then Movalis® Tablets (R)Movalis® Tablets (R), Then Movalis® Capsules (T)
Started1313
Completed1313
Not completed00
Washout Period of 1 Week
Participant flow — Washout Period of 1 Week
MilestoneMovalis® Capsules (T), Then Movalis® Tablets (R)Movalis® Tablets (R), Then Movalis® Capsules (T)
Started1313
Completed1313
Not completed00
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneMovalis® Capsules (T), Then Movalis® Tablets (R)Movalis® Tablets (R), Then Movalis® Capsules (T)
Started1313
Completed1313
Not completed00

Outcome measures

PrimaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-t). Standard error is actually Geometric standard error.

Time frame:
Baseline (pre-dose), 0.5 hours (h), 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 10.0h, 12.0h, 24.0h, 32.0h, 48.0h and 72.0h post-dose
Reported as:
Geometric least squares mean · Nanogram (ng)·hour (h)/ mililiter(mL)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t)
Nanogram (ng)·hour (h)/ mililiter(mL)Movalis® Capsules (T)Movalis® Tablets (R)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-t)27870.56 ± 1.0630051.25 ± 1.06
Statistical analysis
  • Movalis® Capsules (T) vs Movalis® Tablets (R) · Geometric mean ratio t/r, %: 92.74 · 95% CI 89.02 to 96.62Standard error of the mean is actually intra individual coefficient of variation.
PrimaryMaximum Measured Concentration of the Analyte in Plasma (Cmax)

Maximum measured concentration of the analyte in plasma (Cmax). Standard error is actually Geometric standard error.

Time frame:
Baseline (pre-dose), 0.5 hours(h), 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 10.0h, 12.0h, 24.0h, 32.0h, 48.0h and 72.0h post-dose
Reported as:
Geometric least squares mean · ng/mL
Maximum Measured Concentration of the Analyte in Plasma (Cmax)
ng/mLMovalis® Capsules (T)Movalis® Tablets (R)
Maximum Measured Concentration of the Analyte in Plasma (Cmax)1131.12 ± 1.041432.83 ± 1.04
Statistical analysis
  • Movalis® Capsules (T) vs Movalis® Tablets (R) · Geometric mean ratio t/r, %: 78.94 · 90% CI 73.70 to 84.56Standard error of the mean is actually intra individual coefficient of variation.
SecondaryArea Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞). Standard error is actually Geometric standard error.

Time frame:
Baseline (pre-dose), 0.5 hours(h), 1.0h, 2.0h, 3.0h, 4.0h, 5.0h, 6.0h, 7.0h, 8.0h, 10.0h, 12.0h, 24.0h, 32.0h, 48.0h and 72.0h post-dose
Reported as:
Geometric least squares mean · ng·h/mL
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
ng·h/mLMovalis® Capsules (T)Movalis® Tablets (R)
Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)32863.87 ± 1.0933867.43 ± 1.09
Statistical analysis
  • Movalis® Capsules (T) vs Movalis® Tablets (R) · Geometric mean ratio t/r, %: 97.04 · 90% CI 92.57 to 101.72Standard error of the mean is actually intra individual coefficient of variation.

Adverse events

Collected over From first drug administration until 7 days after the last drug administration, ie., up to 8 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Movalis® Capsules (T)0/26 (0%)0/26 (0%)0/26 (0%)
Movalis® Tablets (R)0/26 (0%)0/26 (0%)0/26 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Movalis® Capsules (T), Then Movalis® Tablets (R)Movalis® Tablets (R), Then Movalis® Capsules (T)Total
Mean30.5 ± 7.429.5 ± 6.030.0 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Movalis® Capsules (T), Then Movalis® Tablets (R)Movalis® Tablets (R), Then Movalis® Capsules (T)Total
Female101121
Male325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Paticipants)Movalis® Capsules (T), Then Movalis® Tablets (R)Movalis® Tablets (R), Then Movalis® Capsules (T)Total
Caucasian131326
08

Study locations

1 site
  • City Clinical Hospital named after V.P. Demikhova Department of Health of Moscow
    Moscow, 109263, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization). Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to: find information in order to request access to clinical study data, for listed studies. request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement'.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Oct 2018, 0 months.

Results were first posted in Nov 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2018
First posted
Sep 25, 2018
StartActual
Oct 5, 2018
Primary completionActual
Oct 30, 2018
CompletionActual
Nov 6, 2018
Results first posted
Nov 22, 2019
Last update
Nov 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03684265
Responsible party
Sponsor
First posted
Sep 25, 2018
Start date
Oct 5, 2018
Primary completion
Oct 30, 2018
Completion
Nov 6, 2018
Results posted
Nov 22, 2019
Last update
Nov 22, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion